Cassella James V
- SEC CIK
- 0001353528
No open-market purchases or sales filed in the past year.
Current role at each company
- TRVI Trevi Therapeutics, Inc.Chief Development Officeras of Feb 20, 2026
- CNCE Concert Pharmaceuticals, Inc.Chief Development Officeras of Mar 6, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Cassella James V as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CNCE Concert Pharmaceuticals, Inc.
Chief Development Officer6 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 16, 2023 (view filing) | Feb 15 | 1 day | Cassella James VChief Development Officer | SSale | −3.76K | $8.34 | −$31.4K | −2.1%173.1K after | |
| Jan 31, 2023 (view filing) | Jan 30 | 1 day | Cassella James VChief Development Officer | SSale | −10.1K | $8.35 | −$84.4K | −5.4%176.8K after | |
| Jan 9, 2023 (view filing) | Jan 6 | 3 days | Cassella James VChief Development Officer | SSale | −2.89K | $7.25 | −$21.0K | −1.5%186.9K after | |
| Feb 16, 2022 (view filing) | Feb 14 | 2 days | Cassella James VChief Development Officer | SSale | −3.76K | $3.09 | −$11.6K | −1.9%189.8K after | |
| Jan 7, 2022 (view filing) | Jan 5 | 2 days | Cassella James VChief Development Officer | SSale | −2.89K | $3.19 | −$9.23K | −3.4%83.1K after | |
| Aug 17, 2021 (view filing) | Aug 16 | 1 day | Cassella James VChief Development Officer | SSale | −8.09K | $3.28 | −$26.5K | −8.6%86.0K after |